The High-Grade Glioma drugs in development market research report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for High-Grade Glioma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued products.
GlobalData tracks 104 drugs in development for High-Grade Glioma by 93 companies/universities/institutes. The top development phase for High-Grade Glioma is phase ii with 40 drugs in that stage. The High-Grade Glioma pipeline has 89 drugs in development by companies and 15 by universities/ institutes. Some of the companies in the High-Grade Glioma pipeline products market are: Novartis, StemGen and Bristol-Myers Squibb.
The key targets in the High-Grade Glioma pipeline products market include Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1), and Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1).
The key mechanisms of action in the High-Grade Glioma pipeline product include Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1) Inhibitor with five drugs in Phase III. The High-Grade Glioma pipeline products include 20 routes of administration with the top ROA being Oral and 16 key molecule types in the High-Grade Glioma pipeline products market including Small Molecule, and Cell Therapy.
High-Grade Glioma overview
High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy.
For a complete picture of High-Grade Glioma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
